Fabian Model
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fabian Model has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Brochet
Université de Bordeaux, Inserm, U1215, Neurocentre Magendie, Bordeaux, France
2 shared publications - Jerry S. Wolinsky
Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA
2 shared publications - Robert T. Naismith
Department of Neurology, Washington University, St. Louis, MO, USA
2 shared publications - Stephen L. Hauser
University of California, San Francisco
2 shared publications - Xavier Montalban
Centro de Esclerosis Múltiple de Cataluña y Departamento de Neurología, Hospital Universitario Vall d’Hebron, 08035 Barcelona, España
2 shared publications - Alexander Mustea
Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany
1 shared publication
Latest Publications
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
TREM2 AD risk variants impact pTau and microglia and astrocyte related biomarkers in cognitively unimpaired subjects
Background: In the central nervous system, Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is expressed primarily in microglia. TREM2 receptors are important for microglial functions including phagocytosis, lipid metabolism and inflammatory responses. TREM2 coding variants (e.g. R47H rs75932628 and R62H rs143332484) increase the risk of late onset Alzheimer’s Diseases (AD). However, the impact of TREM2 risk variants on microglial cell functions in humans remains to be elucidated.Method: CSF and plasma samples were collected from AD patients (n = 120) and cognitively unimpaired control subjects (n = 53) with subjective complaints who do not meet biomarker‐based criteria for AD diagnosis. TREM2 AD risk variant carriers (n = 52) were screened from over 6000 samples of the Amsterdam dementia cohort using a combination of genotype array and exome sequencing. We performed extensive biomarker analysis of CSF and plasma samples with multidisciplinary approaches. We compared the effect of TREM2 mutations on AD disease and microglial and astrocytic biomarkers in AD patients and in cognitively unimpaired control subjects, respectively. A linear model was used with age and gender adjusted for the data analysis.Result: We found higher levels of pTau181 and pTau231 in CSF and plasma in cognitively unimpaired TREM2 mutation carriers compared to non‐carriers, while no difference was observed between TREM2 genotype among the AD patients. Microglia and astrocyte biomarkers including sTREM2, FABP3, OLR1, YKL40 and GFAP were higher in the CSF from cognitively unimpaired TREM2 mutation carriers compared to non‐carriers, but no difference was detected between TREM2 genotype among the AD patients. We also found different levels of lipid metabolites in CSF and plasma samples from the TREM2 mutation carriers compared to non‐carriers in both AD patients and cognitively unimpaired control subjects.Conclusion: TREM2 AD risk variants in cognitively unimpaired subjects increase pTau biomarkers and microglial and astrocytic related biomarkers. In AD patients, the biomarker differences between TREM2 genotype are diminished likely due to the extensive microglial responses to AD pathology. Moreover, our data indicates TREM2 AD risk variants may impact lipid‐metabolic processes in microglial cells. These data provide the biomarker insights on how TREM2 mutations may increase the risk of AD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessTREM2 AD risk variants impact pTau and microglia and astrocyte related biomarkers in cognitively unimpaired subjects
Background: In the central nervous system, Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is expressed primarily in microglia. TREM2 receptors are important for microglial functions including phagocytosis, lipid metabolism and inflammatory responses. TREM2 coding variants (e.g. R47H rs75932628 and R62H rs143332484) increase the risk of late onset Alzheimer’s Diseases (AD). However, the impact of TREM2 risk variants on microglial cell functions in humans remains to be elucidated.Method: CSF and plasma samples were collected from AD patients (n = 120) and cognitively unimpaired control subjects (n = 53) with subjective complaints who do not meet biomarker‐based criteria for AD diagnosis. TREM2 AD risk variant carriers (n = 52) were screened from over 6000 samples of the Amsterdam dementia cohort using a combination of genotype array and exome sequencing. We performed extensive biomarker analysis of CSF and plasma samples with multidisciplinary approaches. We compared the effect of TREM2 mutations on AD disease and microglial and astrocytic biomarkers in AD patients and in cognitively unimpaired control subjects, respectively. A linear model was used with age and gender adjusted for the data analysis.Result: We found higher levels of pTau181 and pTau231 in CSF and plasma in cognitively unimpaired TREM2 mutation carriers compared to non‐carriers, while no difference was observed between TREM2 genotype among the AD patients. Microglia and astrocyte biomarkers including sTREM2, FABP3, OLR1, YKL40 and GFAP were higher in the CSF from cognitively unimpaired TREM2 mutation carriers compared to non‐carriers, but no difference was detected between TREM2 genotype among the AD patients. We also found different levels of lipid metabolites in CSF and plasma samples from the TREM2 mutation carriers compared to non‐carriers in both AD patients and cognitively unimpaired control subjects.Conclusion: TREM2 AD risk variants in cognitively unimpaired subjects increase pTau biomarkers and microglial and astrocytic related biomarkers. In AD patients, the biomarker differences between TREM2 genotype are diminished likely due to the extensive microglial responses to AD pathology. Moreover, our data indicates TREM2 AD risk variants may impact lipid‐metabolic processes in microglial cells. These data provide the biomarker insights on how TREM2 mutations may increase the risk of AD.
- 3 February 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S55
A blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II
- 3 February 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S55
A blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II
- 14 November 2019
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 90 (12) , e47.2-e47
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis
Background The efficacy and safety of ocrelizumab in relapsing multiple sclerosis were demonstrated in the double-blind control period of the Phase III OPERA I/II trials (NCT01247324/NCT01412333). Here we assessed the efficacy of switching to or maintaining ocrelizumab therapy after 3 years’ follow-up in the open-label extensions (OLEs) of these studies. Methods At OLE commencement, patients continued ocrelizumab (OCR-OCR) or switched from interferon-β-1a (IFN) to ocrelizumab (IFN-OCR). Adjusted annualised relapse rate (ARR) and time-to-onset of 24-week confirmed disability progression (CDP24) were analysed. Results Among IFN-OCR patients, ARR decreased from 0.20 in the year pre-switch to 0.10, 0.08 and 0.07 at Years 1, 2 and 3 post-switch. OCR-OCR continuers maintained low ARRs through the year pre-OLE and the 3 years of OLE (0.13, 0.11, 0.08, 0.07). CDP24 was less frequent in OCR-OCR continuers versus IFN-OCR switchers in the year pre-switch and Years 1, 2 and 3 of OLE (7.7%/12.0%, 10.1%/15.6%, 13.9%/18.1% and 16.1%/21.3%; pConclusions Switching from IFN to ocrelizumab at the start of the OLE provided rapid reductions in ARR, maintained throughout the 3-year follow-up. After 5 years’ follow-up, patients who initiated ocrelizumab 2 years earlier accrued significant, sustained reductions in disability progression compared with patients switching from IFN. Disclosures Sponsored by F. Hoffmann-La Roche Ltd; writing and editorial assistance was provided by Articulate Science, UK, and funded by F. Hoffmann-La Roche Ltd.
- 14 November 2019
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 90 (12) , e47.2-e47
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis
Background The efficacy and safety of ocrelizumab in relapsing multiple sclerosis were demonstrated in the double-blind control period of the Phase III OPERA I/II trials (NCT01247324/NCT01412333). Here we assessed the efficacy of switching to or maintaining ocrelizumab therapy after 3 years’ follow-up in the open-label extensions (OLEs) of these studies. Methods At OLE commencement, patients continued ocrelizumab (OCR-OCR) or switched from interferon-β-1a (IFN) to ocrelizumab (IFN-OCR). Adjusted annualised relapse rate (ARR) and time-to-onset of 24-week confirmed disability progression (CDP24) were analysed. Results Among IFN-OCR patients, ARR decreased from 0.20 in the year pre-switch to 0.10, 0.08 and 0.07 at Years 1, 2 and 3 post-switch. OCR-OCR continuers maintained low ARRs through the year pre-OLE and the 3 years of OLE (0.13, 0.11, 0.08, 0.07). CDP24 was less frequent in OCR-OCR continuers versus IFN-OCR switchers in the year pre-switch and Years 1, 2 and 3 of OLE (7.7%/12.0%, 10.1%/15.6%, 13.9%/18.1% and 16.1%/21.3%; pConclusions Switching from IFN to ocrelizumab at the start of the OLE provided rapid reductions in ARR, maintained throughout the 3-year follow-up. After 5 years’ follow-up, patients who initiated ocrelizumab 2 years earlier accrued significant, sustained reductions in disability progression compared with patients switching from IFN. Disclosures Sponsored by F. Hoffmann-La Roche Ltd; writing and editorial assistance was provided by Articulate Science, UK, and funded by F. Hoffmann-La Roche Ltd.
- 1 November 2018
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 26, 264-265
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial
- 1 November 2018
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 26, 264-265
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial
- Open Access
- 15 January 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (2) , 599-608
Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue
Regulatory T-cells (Treg) have been the focus of immunologic research due to their role in establishing tolerance for harmless antigens versus allowing immune responses against foes. Increased Treg frequencies measured by mRNA expression or protein synthesis of the Treg marker FOXP3 were found in various cancers, indicating that dysregulation of Treg levels contributes to tumor establishment. Furthermore, they constitute a key target of immunomodulatory therapies in cancer as well as transplantation settings. One core obstacle for understanding the role of Treg, thus far, is the inability of FOXP3 mRNA or protein detection methods to differentiate between Treg and activated T cells. These difficulties are aggravated by the technical demands of sample logistics and processing. Based on Treg-specific DNA demethylation within the FOXP3 locus, we present a novel method for monitoring Treg in human peripheral blood and solid tissues. We found that Treg numbers are significantly increased in the peripheral blood of patients with interleukin 2–treated melanoma and in formalin-fixed tissue from patients with lung and colon carcinomas. Conversely, we show that immunosuppressive therapy including therapeutic antibodies leads to a significant reduction of Treg from the peripheral blood of transplantation patients. In addition, Treg numbers are predictively elevated in the peripheral blood of patients with various solid tumors. Although our data generally correspond to data obtained with gene expression and protein-based methods, the results are less fluctuating and more specific to Treg. The assay presented here measures Treg robustly in blood and solid tissues regardless of conservation levels, promising fast screening of Treg in various clinical settings. [Cancer Res 2009;69(2):599–608]
- 15 January 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (2) , 599-608
Open AccessQuantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue
Regulatory T-cells (Treg) have been the focus of immunologic research due to their role in establishing tolerance for harmless antigens versus allowing immune responses against foes. Increased Treg frequencies measured by mRNA expression or protein synthesis of the Treg marker FOXP3 were found in various cancers, indicating that dysregulation of Treg levels contributes to tumor establishment. Furthermore, they constitute a key target of immunomodulatory therapies in cancer as well as transplantation settings. One core obstacle for understanding the role of Treg, thus far, is the inability of FOXP3 mRNA or protein detection methods to differentiate between Treg and activated T cells. These difficulties are aggravated by the technical demands of sample logistics and processing. Based on Treg-specific DNA demethylation within the FOXP3 locus, we present a novel method for monitoring Treg in human peripheral blood and solid tissues. We found that Treg numbers are significantly increased in the peripheral blood of patients with interleukin 2–treated melanoma and in formalin-fixed tissue from patients with lung and colon carcinomas. Conversely, we show that immunosuppressive therapy including therapeutic antibodies leads to a significant reduction of Treg from the peripheral blood of transplantation patients. In addition, Treg numbers are predictively elevated in the peripheral blood of patients with various solid tumors. Although our data generally correspond to data obtained with gene expression and protein-based methods, the results are less fluctuating and more specific to Treg. The assay presented here measures Treg robustly in blood and solid tissues regardless of conservation levels, promising fast screening of Treg in various clinical settings. [Cancer Res 2009;69(2):599–608]